2026-08-09T03:33:31Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/270712025-12-18T12:57:40Zcom_20.500.12105_2273com_20.500.12105_2202col_20.500.12105_19571

00925njm 22002777a 4500 dc Sanz-Sánchez, Jorge author Santos Martínez, Sandra author Rumiz González, Eva author Oteo Domínguez, Juan Francisco author Tejada Ponce, David author Gómez Menchero, Antonio author Sánchez Elvira, Guillermo author Fuertes Ferre, Georgina author Rivero Crespo, Fernando author Lukic Otanovic, Antonela author Díaz Fernández, José author Galindo Fernández, Eladio author Urbano Carrillo, Cristóbal author Salvatella Giralt, Neus author Torres Sánchez, Mauricio author García Touchard, Arturo author Ibáñez Cabeza, Borja author Stefanini, Giulio author Alfonso Manterola, Fernando author García García, Héctor author Amat-Santos, Ignacio J author 2025-05-22 Primary percutaneous coronary intervention (PCI) with drug-eluting stent implantation (DES) is the standard of treatment in patients presenting with ST-segment elevation myocardial infarction (STEMI). However, target lesion failure can occur due to stent underexpansion, malapposition, hypersensitivity, fracture, and neoatherosclerosis. Drug-coated balloons (DCB) represent a potential alternative supported by the concept of "leaving nothing behind." The aim is to compare a reduced stent strategy based on DCB- with DES-PCI in patients presenting with STEMI. Prospective, pragmatic, multicenter, noninferiority, randomized clinical trial. A total of 1 272 patients presenting with STEMI will be randomized to any paclitaxel-DCB vs any sirolimus-DES (both with CE approval) for all culprit and nonculprit lesions during PCI. The primary endpoint will be target-lesion failure: cardiac death, target-vessel myocardial infarction, or ischemia-driven target lesion revascularization at 12-month follow-up. An independent clinical events committee masked to treatment allocation will adjudicate all suspected events. Clinical follow-up will be performed after 1 month (30 days±5 days) and 1 year (365 days±30 days). An extended follow-up at 3, 5, and 10 years is planned. The COPERNICAN trial will be the first randomized study comparing clinical outcomes of DCB vs DES in STEMI patients. Rev Esp Cardiol (Engl Ed). 2025 May 22:S1885-5857(25)00150-1. REVISTA ESPANOLA DE CARDIOLOGIA 40412715 https://hdl.handle.net/20.500.12105/27071 BFA Balón farmacoactivo DCB DES Drug-coated balloon Drug-eluting stent implantation IAMCEST Infarto agudo de miocardio con elevación del segmento ST SFA ST-segment elevation myocardial infarction STEMI Stent farmacoactivo Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with STEMI: the COPERNICAN trial.